Skip to main content

What the FDA labels say about taking them together

Ritonavir and toremifene

Toremifene's FDA label of November 13, 2024 names ritonavir in its drug interactions section; the ritonavir label PlainMeds reads does not name toremifene. The toremifene label: “The administration of FARESTON with agents that are strong CYP3A4 inhibitors increase the steady-state concentration in serum and should be avoided.”

Check it at the source: the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.); the toremifene FDA label on DailyMed (effective November 13, 2024, Kyowa Kirin, Inc.).

What does the ritonavir label say about toremifene?

Ritonavir's label (effective July 23, 2026) does not name toremifene in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed

What does the toremifene label say about ritonavir?

Toremifene label, drug interactions

The administration of FARESTON with agents that are strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole) increase the steady-state concentration in serum and should be avoided.

Source: FDA drug label (Fareston), Kyowa Kirin, Inc., effective November 13, 2024 (SPL set 2cab8dd1-3a10-48e6-86ce-0e5275ed49e5), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

7Ritonavir generic labelers
2Toremifene generic labelers
RitonavirToremifene
Labeled forHIVBreast cancer
Boxed warningYesYes
Pharmacy cost (NADAC)$0.607 per tablet 100 mg tablet$19.60 per tablet 60 mg tablet
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?